Mineralys Therapeutics announced on March 10, 2025, positive topline data from its pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials evaluating lorundrostat for uncontrolled or resistant hypertension. Both trials successfully achieved statistical significance in their primary efficacy endpoints and demonstrated a favorable safety and tolerability profile.
In the Launch-HTN trial, the 50 mg dose of lorundrostat achieved a 9.1 mmHg placebo-adjusted reduction in systolic blood pressure at week 6, which was sustained with an 11.7 mmHg placebo-adjusted reduction at week 12. The Advance-HTN trial met its primary endpoint with a 7.9 mmHg placebo-adjusted reduction in 24-hour ambulatory systolic blood pressure at week 12 for the 50 mg dose.
These clinically meaningful results position lorundrostat as a potential transformative new therapy for millions of patients with uncontrolled hypertension. The company plans to present full results from Advance-HTN on March 29, 2025, at the American College of Cardiology Scientific Sessions, further detailing the drug's profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.